169 related articles for article (PubMed ID: 21245444)
21. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
Lemaire S; Van Bambeke F; Tulkens PM
Int J Antimicrob Agents; 2011 Jul; 38(1):52-9. PubMed ID: 21596526
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
24. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
[TBL] [Abstract][Full Text] [Related]
25. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
[TBL] [Abstract][Full Text] [Related]
27. Time-kill activity of the streptogramin NXL 103 against Gram-positive and -negative bacteria.
Pankuch GA; Lin G; Clark C; Appelbaum PC
Antimicrob Agents Chemother; 2011 Apr; 55(4):1787-91. PubMed ID: 21245439
[TBL] [Abstract][Full Text] [Related]
28. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms.
Flamm RK; Rhomberg PR; Simpson KM; Farrell DJ; Sader HS; Jones RN
Antimicrob Agents Chemother; 2015 Mar; 59(3):1751-4. PubMed ID: 25583717
[TBL] [Abstract][Full Text] [Related]
29. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
30. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
Sobottka I; Neumann S; Laufs R
Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
[TBL] [Abstract][Full Text] [Related]
32. Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria.
Pormohammad A; Moradi M; Hommes JW; Pujol E; Naesens L; Vázquez S; Surewaard BGJ; Zarei M; Vazquez-Carrera M; Turner RJ
Microbiol Spectr; 2024 Jun; 12(6):e0007124. PubMed ID: 38700321
[TBL] [Abstract][Full Text] [Related]
33. In vitro comparison of ciprofloxacin to parenteral antibiotics.
Speciale A; Caccamo F; Nicoletti G
J Chemother; 1989 Jul; 1(4 Suppl):154-6. PubMed ID: 16312349
[No Abstract] [Full Text] [Related]
34. In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1987; 33(6):419-27. PubMed ID: 3428009
[TBL] [Abstract][Full Text] [Related]
35. [Activity of ciprofloxacin in vitro].
Ferrara A; Donnetta A; Alessandrini R; Grassi FA; Gialdroni Grassi G
G Ital Chemioter; 1986; 33(2-3):99-107. PubMed ID: 3678720
[No Abstract] [Full Text] [Related]
36. Antibacterial activity of lomefloxacin.
Leigh DA; Tait S; Walsh B
J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
[TBL] [Abstract][Full Text] [Related]
37. Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.
Barnes KB; Hamblin KA; Richards MI; Laws TR; Vente A; Atkins HS; Harding SV
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438936
[No Abstract] [Full Text] [Related]
38. Fishmeal extract agar--a new antibiotic sensitivity test medium.
Subbannayya K; Raghunath P; Rao VA; Nayak BS
Indian J Exp Biol; 2002 Aug; 40(8):960-2. PubMed ID: 12597032
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of ciprofloxacin tethered bis-1,2,3-triazole conjugates as potent antibacterial agents.
Kant R; Singh V; Nath G; Awasthi SK; Agarwal A
Eur J Med Chem; 2016 Nov; 124():218-228. PubMed ID: 27592391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
